JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Sana Biotechnology Inc

Avatud

SektorTervishoid

5.49 1.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.36

Max

5.61

Põhinäitajad

By Trading Economics

Sissetulek

-44M

-94M

Kasumimarginaal

-321.09

Töötajad

194

EBITDA

-48M

-95M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+57.14% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. nov 2025

Turustatistika

By TradingEconomics

Turukapital

609M

1.4B

Eelmine avamishind

4.39

Eelmine sulgemishind

5.49

Uudiste sentiment

By Acuity

50%

50%

154 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. okt 2025, 23:25 UTC

Tulu

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. okt 2025, 23:18 UTC

Tulu

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. okt 2025, 22:20 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. okt 2025, 22:13 UTC

Tulu

Wal-Mart de Mexico Net Profit Falls in 3Q

28. okt 2025, 21:38 UTC

Tulu

Correction to Visa Sales Jump Article

28. okt 2025, 21:17 UTC

Tulu

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. okt 2025, 21:07 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- Update

28. okt 2025, 21:02 UTC

Tulu

Mondelez Tempers Outlook as Costs Rise

28. okt 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. okt 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. okt 2025, 23:02 UTC

Tulu

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. okt 2025, 23:01 UTC

Tulu

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. okt 2025, 22:46 UTC

Tulu

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. okt 2025, 22:45 UTC

Tulu

SK Hynix 3Q Net KRW12.6T >000660.SE

28. okt 2025, 22:44 UTC

Tulu

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. okt 2025, 22:43 UTC

Tulu

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. okt 2025, 22:42 UTC

Tulu

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. okt 2025, 22:20 UTC

Tulu

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. okt 2025, 22:02 UTC

Tulu

Review & Preview: Earnings Extravaganza -- Barrons.com

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

28. okt 2025, 21:42 UTC

Market Talk
Tulu

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. okt 2025, 21:20 UTC

Tulu

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. okt 2025, 21:19 UTC

Tulu

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. okt 2025, 21:18 UTC

Tulu

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

57.14% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD  57.14%

Kõrge 12 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

154 / 373 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat